ArticleVaccines2026

Real-World Utilization of the Novavax Adjuvanted Recombinant Protein COVID-19 Vaccine in France During the 2022-2024 Period.

Stephanie H Read et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.